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Abstract: As caterpillars detect the presence of predators and secrete poison, herein, we show
an innovative and highly effective cancer therapeutic system using biocompatible chitosan nanofiber
(CNf) installed with a pH-responsive motif that senses tumor extracellular pH, pHe , prior to delivering
dual-modal light-activatable materials for tumor reduction. The filamentous nanostructure of CNf is
dynamic during cell interaction and durable in blood circulation. Due to its amine group, CNf uptakes
a large amount of photothermal gold nanoparticles (AuNPs, >25 wt %) and photodynamic chlorin e6
(Ce6, >5 wt %). As the innovative CNf approaches tumors, cationic CNf effectively discharges AuNPs
connected to the pH-responsive motif via electrostatic repulsion and selectively binds to tumor cells
that are generally anionic, via the electrostatic attraction accompanied by CNf. We demonstrated via
these actions that the endocytosed Ce6 (on CNf) and AuNPs (free from CNf) significantly elicited
tumor cell death under light irradiation. As a result, the synergistic interplay of thermogenesis and
photodynamic action was observed to switch on at the pHe , resulting in a striking reduction in tumor
formation and growth rate upon light exposure.
Keywords: pH-sensitive chitosan nanofiber; photothermal gold nanoparticles; photodynamic chlorin e6;
synergistic tumor therapy; tumor-targeted drug delivery system

1. Introduction
The tumor and its key issues remain a burden on human health and the health care system.
Although current clinical approaches, such as surgery, chemotherapy, and radiotherapy, have been
applied for therapeutic tumor removal or to preclude tumor development, these treatments are
associated with many side effects, complications, and drug resistance. To minimize such traumas,
several drug delivery systems (DDSs) have been suggested as anti-tumor agents for use as internal
medicine methodologies. However, studies are ongoing in the quest for more effective, astute, rapid,
and safer next-generation DDS tools for tumor therapy [1–7].
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The anti-predatory behavior of caterpillars functions as an approach for next-generation DDS.
Poisonous caterpillars have evolved their adaptive strategies owing to their constant struggle against
predators such as spiders. Poison is used for primary defense under specific environmental conditions
such as the detection of predatory behavior. Similarly, an ideal DDS of an antitumor drug should be
effectively released from the carrier when a tumor-specific environment is perceived. To understand a
caterpillar-mimetic DDS, the following two criteria for material design were established: (1) an effective
tumor-targeted drug (poison) and (2) an innovative environmental-recognition and worm-like structure
to function as the drug carrier (predator recognition) [1–7].
As an anti-tumor weapon, we have selected dual-modal phototherapy where thermogenesis-based
photothermal therapy (PTT) is combined with reactive oxygen species (ROS)-based photodynamic
therapy (PDT). PTT employs the conversion of light to heat energy to elicit hyperthermia in tumor
regions using gold nanoparticles (AuNPs) or graphene oxide. PDT, on the other hand, relies on ROS
production when a photosensitizer such as chlorin e6 (Ce6) reacts with oxygen present in tissues to kill
tumor cells during irradiation [1–7]. Since sole-modal therapy has failed to manage the rising rates in
various types of diseases, combinatorial treatments have been widely considered and have garnered a
significant amount of interest [8–12]. Agreeing with this trend, there is a growing appreciation for the
integration of PTT and PDT to function as a highly effective approach in tumor control [13–15].
As an innovative vehicle for photosensitizers, we have designed a biocompatible and pH-sensitive
worm-like nanofiber. Chitosan nanofibers (CNfs) are a promising backbone for drug vehicles based
on the following three rationales: (1) CNf is biomass-derived and biodegradable [16–20]. CNf is
chemically modifiable for drug loading owing to its abundance in amine groups and its association
with a relatively low immune reaction and disease transfer possibility, unlike animal-derived collagen
fibers. (2) CNf is positively charged and thus can serve as a tumor extracellular pH (pHe )-responsive
carrier. If CNf was employed to carry pH-sensitive proton-accepting payloads, a safe transport of the
payloads to the tumor site at physiological pH (7.4) would occur. However, sudden destabilization or
disintegration at pHe (pH 6.8) would also result, owing to the repulsive forces of the positive charges
when there is an efficient release of payloads near the tumor [21–25]. Furthermore, CNf covalently
conjugated to a drug can strongly bind to the anionic tumor. (3) CNf has a worm-like fiber structure.
It has been noted that the shape of DDS tools can affect the journey of particles after entering the body.
Filamentous nanostructures have durable circulation in blood and efficient cellular internalization via
the adsorptive endocytic pathway [26,27]. CNf may therefore have temporal and spatial advantages as
a potent delivery vehicle for tumor-targeted DDS.
The objective of this study was to develop pHe -sensitive filamentous chitosan-based nanomaterial
for synergistic tumor therapy via the combination of PTT and PDT. Beyond their role as building blocks,
we also included a variety of ingredients on the chitosan backbone to serve as decorations (Figure 1a).
pHe -sensitive dopamine-2,3-dimethylmaleic acid (DMMA) [22,23] was coated on a heat-producible
AuNP [28,29] to synthesize AuNP-dopamine-DMMA (AuDD). A photosensitizer, Ce6 [5],
was covalently attached to the body of the chitosan nanofiber to synthesize CNf-Ce6. We also
electrostatically linked negatively charged bovine serum albumin (BSA) to the cationic CNf-Ce6
to improve its stability as a drug delivery carrier during blood circulation [30]. In a neutral pH
environment, AuDD is linked to the chitosan backbone owing to its electrostatic interaction (Figure 1b).
However, AuDD is removable from the cationic chitosan backbone at acidic pHe , an action mainly
ascribed to the change in charge of DMMA. Hence, based on the unique pHe -involved strategy,
our DDS agent (CNf), which was covalently grafted to Ce6 and electrostatically coupled to AuDD and
BSA (AuDD/BSA@CNf-Ce6), was designed to be pHe -sensitively transformed to release individual
antitumor payloads of Ce6 and AuDD. The separated CNf-Ce6 and AuDD would also react with the
negatively charged tumor cell surface, enhancing their uptake into the tumor cells. The notion of
tumor degeneration via biocompatible CNf-based phototherapy with pHe selectivity would serve as a
novel and fundamental development for next-generation DDS. This pHe -sensitive CNf may be more
significant than any known nanofiber systems that have been developed to date.
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(Logan, UT, USA). The BCA protein assay kit was bought from Thermo Fisher Scientific Inc. (Walthan,
MA, USA). Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute (RPMI)
1640 medium, phosphate-buffered saline (PBS), ethylenediaminetetraacetic acid (EDTA), fetal bovine
serum (FBS), penicillin, and streptomycin were purchased from Welgene Inc. (Seoul, Korea). Wheat
Germ Agglutinin-Alexa Fluor® 488 conjugate (WGA-Alexa Fluor® 488) was purchased from Life
Technologies (Carlsbad, CA, USA). The Cell Counting Kit-8 (CCK-8) was obtained from Dojindo
Molecular Technologies Inc. (Santa Clara, CA, USA). FITC annexin V apoptosis detection kit I was
acquired from BD Pharmingen (San Diego, CA, USA).
2.2. Preparation of Chitosan Nanofiber (CNf)
The α-chitin powder (5 g) was immersed in a 30 wt % NaOH aqueous solution (125 mL). The suspension
was then heated at 80 ◦ C for 4 h in a nitrogen atmosphere followed by centrifugation at 10,000 rpm for
10 min at 5 ◦ C. After the removal of the supernatant, the pellet was re-constituted in deionized (DI) water
(125 mL). The base dilution processes were repeated three times. The suspension was then dialyzed with DI
water until a pH of 7 was obtained. The concentration of the suspension was adjusted to 1 wt % by adding
DI water. The pH of the suspension was adjusted to 4 by adding several drops of acetic acid, followed
by homogenization using a high-performance grinder (MKCA6-3; Masuko Sangyo Co., Ltd., Kawaguchi,
Japan) with a rotation speed of 1500 rpm. The grinder treatment was performed with a clearance gauge
of −1.5 (corresponding to a 0.15 mm shift) from the zero position. After nanofibrillization, the purified
suspension was ultrasonicated for 10 min (amplitude, 50%; pulse on, 10 s; and pulse off, 5 s) by a 750 W
probe ultrasonic processor (Sonics, Vibra cell, Sonic & Materials, Inc., Newtown, CT, USA). The aqueous
CNf suspension or its freeze-dried form was stored at 4 ◦ C [31]. The degree of deacetylation of the CNf
material was confirmed using a Nicolet iS50 FT-IR spectrometer (Thermo Fisher Scientific, Walthan, MA,
USA) and via titrating the amine groups on the surface of CNf [32,33].
2.3. Synthesis of AuNP-Dopamine-DMMA (AuDD)
To prepare AuDD, we first reacted dopamine (1 g) with 2,3-dimethylmaleic anhydride (1.7 g) in
DMF (15 mL) containing TEA (1 mL) and pyridine (1 mL) at 25 ◦ C for 3 d to produce dopamine-DMMA.
The solution was recrystallized using excessive anhydrous diethyl ether and the precipitate lyophilized.
The yield of dopamine-DMMA was 72.3 ± 4.8 wt % and the chemical structure was analyzed using
a Bruker 300 MHz NMR Spectrometer (Bruker, Ettlingen, Germany). Next, to prepare intact AuNP,
HAuCl4 (2.5 mmoL) in 0.4 M NaOH (19.4 mL) was heated to 110 ◦ C (for 30 min) and then 85 ◦ C
(for 10 min). The obtained AuNP solution was mixed with sodium citrate (0.1 mol; 0.6 mL) for
10 min. The resulting solution was ultracentrifuged at 25,000 rpm for 10 min at 5 ◦ C to separate the
particles from the non-reacted chemicals. The dried precipitates (0.1 g) were sonicated in DI water
for dispersal of the AuNP in the DI water [33]. Dopamine-DMMA (1.5 g) was then mixed with the
AuNP (30 mg) dispersed in DI water (45 mL) and 5 mM sodium tetraborate (20 mL) for 1 d to prepare
AuDD. The concentration of dopamine-DMMA bound to the AuNP was calculated after measuring
the weight of the dried precipitate (AuDD), following ultracentrifugation of the solution at 25,000 rpm
for 10 min at 5 ◦ C. The yield of AuDD was 71.4 ± 4.2 wt % and was calculated after lyophilization.
2.4. Preparation of CNf-Based Nanostructures
To prepare CNf-Ce6, CNf (200 mg) was dissolved in 50 mM HCl (50 mL) using a sonicator (60 Hz
for 30 min) at 25 ◦ C. Ce6 (10 mg) was dissolved in 50 mM NaOH (20 mL) containing EDC (5 mg)
and mixed with the CNf solution for 1 d. The pH of the mixed solution was adjusted to 6.0 by the
gradual addition of 50 mM NaOH. The solution was then dialyzed using a dialysis membrane tube
(Spectra/Por® MWCO 1 kDa) against DI water for 3 d to remove the non-reacted chemicals, prior to
lyophilization. The production yield of CNf-Ce6 was 80.4 ± 3.1 wt %. The amount of Ce6 conjugated
to CNf was determined after analyzing the Ce6 fluorescent intensity in the CNf-Ce6 solution at λex
(450 nm) and λem (670 nm) using a fluorescence RF-5301PC spectrofluorometer (Shimadzu, Japan).
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We then prepared different CNf-Ce6-based nanostructures using AuDD and BSA. CNf-Ce6 (75 mg)
was dispersed in 50 mM HCl (50 mL) using a sonicator (60 Hz for 30 min) at 25 ◦ C. BSA (100 mg)
was dissolved in 50 mM NaOH (20 mL) and mixed with the CNf-Ce6 solution for 8 h [34]. The pH
of the mixed solution was adjusted to 7.4 by the slow addition of 50 mM NaOH. The resulting
precipitation of BSA@CNf-Ce6 was then lyophilized. The production yield of BSA@CNf-Ce6 was
81.5 ± 6.1 wt %. The amount of BSA attached to CNf-Ce6 was calculated using a BCA protein assay
kit. In addition, the dispersed CNf-Ce6 (15 mg) or BSA@CNf-Ce6 (15 mg) in 5 mM sodium tetraborate
solutions (20 mL) was mixed with AuDD (75 mg) at 25 ◦ C for 8 h to generate AuDD@CNf-Ce6
or AuDD/BSA@CNf-Ce6. The resulting solutions were ultracentrifuged at 25,000 rpm for 10 min
at 5 ◦ C to separate the fibers from the nonreacted chemicals. The yields of AuDD@CNf-Ce6 and
AuDD/BSA@CNf-Ce6 were 70.2 ± 4.3 wt % and 73.5 ± 2.9 wt %, respectively and were calculated
after lyophilization. The AuDD concentrations in AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6 were
analyzed using ICP-MS (Thermo Scientific Inc., Walthan, MA, USA).
2.5. Characterization of AuDD and CNf-Based Samples
A Zetasizer 3000 instrument (Malvern Instruments, Westborough, PA, USA) was used to measure
the particle size of AuDD in PBS (pH 7.4, 150 mM). The morphology of the CNf-based samples or
AuDD (0.1 mg/mL, 150 mM PBS pH 7.4) was analyzed using a TEM (JEM 1010, JEOL, Peabody, MA,
USA). The light absorbance of CNf-based samples or AuDD dispersed in PBS (pH 7.4) was observed
using a Cary 1E UV/visible spectrophotometer (Varian Inc., Palo Alto, CA, USA). Visualization of the
CNf-based samples or AuDD at pH 7.4 or 6.8 was monitored using a Nikon microscope equipped with
a visible and NIR hyperspectral camera (CytoViva, Auburn, AL, USA). The zeta-potential change in
CNf-based samples (0.1 mg/mL) at pH 7.4 or 6.8 was measured using Zetasizer 3000. Prior to measuring,
the CNf-based samples were stabilized at 25 ◦ C for 2 h. In addition, when the PBS (150 mM, pH 7.4 or 6.8)
containing CNf-based samples or AuDD was irradiated using an 808 nm laser source (2 W/cm2 for 5 min),
the temperature change in solution was monitored using a probe-type thermometer (905-T1, Testo Inc.,
West Chester, PA, USA) and a thermographic camera (T335, FLIR Systems Inc., Seoul, Korea) [33].
2.6. NIR Fluorescence Analysis
For quantitative analysis, Ce6 fluorescence intensity change in the CNf-based samples
(equivalent to Ce6 10 µg/mL) or free Ce6 (10 µg/mL) at pH 7.4 and 6.8 was measured at λex
(400 nm) and λem (600–750 nm). The NIR fluorescence images from wells containing the CNf
samples (equivalent to Ce6 10 µg/mL) or free Ce6 (10 µg/mL) at pH 7.4 and 6.8 were visualized
using a Kodak image station (λex , 635 nm; λem , 720 nm). The generation of singlet oxygen from the
CNf-based samples or free Ce6 was measured using a fluorescence spectrofluorometer by analyzing the
fluorescence of 9,10-dimethylanthracene (λex , 360 nm; λem , 380–550 nm) [35,36]. Briefly, the CNf samples
(equivalent to Ce6 10 µg/mL) or free Ce6 (10 µg/mL) in PBS (pH 7.4 and 6.8, 150 mM) were mixed with
9,10-dimethylanthracene (20 mM). The resulting solution was then irradiated using a 670 nm laser source
(5.2 mW/cm2 for 10 min). After 1 h incubation, the fluorescence change of 9,10-dimethylanthracene
(Ff –Fs ), calculated by subtracting the fluorescence of CNf samples (Fs ) from the fluorescence of pure
9,1-dimethylanthracene (Ff ), was plotted. The fluorescence of 9,10-dimethylanthracene decreases
because of its selective capture of singlet oxygen [35].
2.7. In Vitro Cellular Uptake Study
Human breast carcinoma MDA-MB-231 cells (obtained from the Korean Cell Line Bank) were
cultured in RPMI-1640 medium containing 10% FBS and 1% penicillin-streptomycin at 37 ◦ C and 5%
CO2 . The cells were incubated with the CNf-based samples (200 µg/mL, equivalent to Ce6 10 µg/mL)
or AuDD (50 µg/mL) at pH 7.4 and 6.8 (incubation time, 8 h). The cellular uptake value [number (N) of
AuDDs taken up per cell] for the AuDD samples was acquired using ICP-MS [33]. For flow cytometry
analysis, the cells were incubated with the CNf-based sample (equivalent to Ce6 10 µg/mL), free Ce6
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(10 µg/mL), or Ce6 dye-tagged AuNP (equivalent to Ce6 10 µg/mL) at pH 7.4 and 6.8 (incubation time: 8 h).
Following incubation, the cells were washed three times with fresh 150 mM PBS (pH 7.4) and analyzed
using a FACSCalibur™ flow cytometer (Becton Dickinson, USA). Visualization of the cells incubated
with AuDD/BSA@CNf-Ce6 sample (200 µg/mL) at pH 7.4 and 6.8 for 8 h were performed using a Nikon
microscope. Next, the cells incubated with each sample (equivalent to Ce6 10 µg/mL) at pH 7.4 and 6.8 for
8 h were stained with DAPI (nuclei stain) and WGA-Alexa Fluor® 488 (cell membrane staining) for cell
analysis using a confocal microscope (Meta LSM710, CarlZeiss, Oberkochen, Germany).
2.8. In Vitro Cell Viability
The phototoxicity of the tumor cells was examined under light irradiation using a 670 or 808 nm
laser source. Cells were incubated with CNf-based samples (200 µg/mL, equivalent to Ce6 10 µg/mL),
free Ce6 (10 µg/mL), or AuDD (50 µg/mL) at pH 7.4 and 6.8 for 8 h followed by three washings using fresh
PBS (150 mM, pH 7.4). The cells were then irradiated at a light intensity of 5.2 mW/cm2 using a 670 nm
laser source for 10 min (PDT) and/or at a light intensity of 2 W/cm2 using an 808 nm laser source for 5 min
(PTT), or repeatedly [5,36]. Cell viability was measured using a CCK-8 assay. In addition, the basal
cytotoxicity of the CNf-based samples or AuDD was evaluated after a 24 h treatment without light
irradiation. To further evaluate cell apoptosis induced by the photothermal/photodynamic treatment
of the AuDD/BSA@CNf-Ce6 sample, the Annexin-V-FITC/PI staining method was performed [37].
MDA-MB-231 cells were first seeded into a 12-well plate at a density of 1 × 104 cells per well at 37 ◦ C in
a 5% CO2 atmosphere for 24 h. The cells were then washed three times with fresh PBS (150 mM, pH 7.4)
to remove the dead cells and were incubated with the AuDD/BSA@CNf-Ce6 sample (200 µg/mL,
equivalent to Ce6 10 µg/mL) dispersed in culture medium (pH 7.4 and 6.8) at 37 ◦ C for 8 h. The cells
were then washed three times with fresh PBS (150 mM, pH 7.4) to remove the AuDD/BSA@CNf-Ce6
samples that were not uptaken, followed by exposure to a 670 nm laser (5.2 mW/cm2 ) for 10 min
(PDT irradiation) and/or an 808 nm laser (2 W/cm2 ) for 5 min (PTT irradiation). After laser irradiation,
the cells were incubated with fresh culture medium at 37 ◦ C for 24 h. Following incubation, the cells
were collected and resuspended in 500 µL of binding buffer, and Annexin V-FITC and PI added,
according to the manufacturer’s recommendation. The treated cells were incubated in the dark for
15 min at 25 ◦ C and then analyzed using FACSCalibur™ flow cytometry.
2.9. Animal Care
All animal experiments were conducted using 6- to 8-week-old female nude mice (BALB/c, nu/nu
mice, Institute of Medical Science, Japan). The nude mice were maintained using the guidelines
(animal ethics number: 2018-016, approved by the Catholic University of Korea) approved by
the Institutional Animal Care and Use Committee (IACUC) of the Catholic University of Korea
(Republic of Korea).
2.10. In Vivo Uptake Test
For the in vivo experiments, female nude mice were inoculated with MDA-MB-231 tumor cells
via subcutaneous injection of 1 × 107 cells suspended in 150 mM PBS (pH 7.4). When tumor volume
reached 100 mm3 , each CNf-based sample (50 mg/kg, equivalent to Ce6 2.5 mg/kg) or free Ce6
(2.5 mg/kg) was intravenously injected into the MDA-MB-231 tumor-bearing nude mice through the
tail vein. Live fluorescent images of the MDA-MB-231 tumor-bearing nude mice were obtained using
an Image Station 4000 MM (Kodak, Rochester, NY, USA). Total photon counts per centimeter squared
per steradian (p/s/cm2 /sr) in the organs were measured using the Image Station 4000 MM. At 8 h
post-injection, the nude mice were sacrificed, and the excised tumor and organs (brain, lung, heart,
liver, kidney, and spleen) analyzed for the biodistribution study.
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2.11. In Vivo Micro-CT Scan
The micro-CT imaging of MDA-MB-231 tumor-bearing nude mice that were intravenously injected
with AuDD/BSA@CNf-Ce6 (50 mg/kg) were obtained at 8 h post-injection using a micro-CT imaging
scanner (CLS140083, PerkinElmer Inc., Waltham, MA, USA) under appropriate anesthesia.
2.12. In Vivo Thermal Imaging
MDA-MB-231 tumor-bearing nude mice that were intravenously injected with the CNf-based
sample (50 mg/kg), AuDD (12.5 mg/kg), or saline (control) were locally irradiated (8 h post-injection) at
a light intensity of 2 W/cm2 using an 808 nm laser source for 5 min (PTT). The thermal body images of
mice were captured using a thermal imaging camera [33].
2.13. Tumor Growth Measurement
MDA-MB-231 tumor-bearing nude mice intravenously injected with the CNf-based sample
(50 mg/kg, equivalent to Ce6 2.5 mg/kg), free Ce6 (2.5 mg/kg), AuDD (12.5 mg/kg), or saline (control),
were locally irradiated (after 8 h injection) at a light intensity of 5.2 mW/cm2 using a 670 nm NIR laser
for 40 min (PDT) and subsequently at a light intensity of 2 W/cm2 using an 808 nm NIR laser for 5 min
(PTT). Tumor volume of nude mice was determined using the following formula: tumor volume =
length × (width)2 /2. In addition, the relative tumor volume change (Vt /V0 ) was calculated from the
ratio of Vt (the tumor volume at a given time) to V0 (the initial tumor volume). Change in body weight
of mice (Wt /W0 ) was calculated from the ratio of Wt (the body weight at a given time) to W0 (the initial
body weight) [33,35].
2.14. Statistics
All results were analyzed via a Student’s t-test or analysis of variance (ANOVA) with p < 0.01
(**) as the significance level. The MINITAB® release 14 statistical software program was used for all
statistical analyses.
3. Results and Discussion
3.1. Synthesis and Characterization of AuDD/BSA@CNf-Ce6
As shown in the schematic illustration (Figure 1b), stepwise synthesis was adopted to prepare the
pHe -responsive AuDD/BSA@CNf-Ce6, the backbone of which was obtained by facile deacetylation
and ultrasonication of shrimp shell-originated α-chitin. The degree of deacetylation was 44.0% as
determined by Fourier transform infrared spectroscopy (Table S1) [31,32]. When measured via the
titration method, the degree of deacetylation was 26.9 ± 3.3%; this lower value is because of the
inaccessibility of protons to the CNf core [38]. Additionally, the degree of DMMA attached to dopamine
(defined as the number of DMMA molecules per dopamine molecules) was estimated as 1.7, based on
calculations using 1 H-NMR peak values at δ 1.6 ppm (–CH3 from DMMA) and δ 2.8 ppm (–CH2 –
from dopamine) (Figure S1). Dopamine-DMMA was coated on the surface of the gold nanoparticle
(AuNP) via catecholic coordination [39,40], resulting in AuDD formation. We obtained a size that
was approximately 24.4 nm in diameter, along with a spherical shape for the AuDD (Figure S2).
To achieve the optimal feeding ratio of AuDD conjugation to the CNf body, we combined 2-, 5-,
and 10-fold AuDD with CNf; the coupled ratios were 7% (AuDD7 @CNf), 24% (AuDD24 @CNf), and
40% (AuDD40 @CNf), respectively. The hyperspectral imaging analysis demonstrated that AuDDs
in red were electrostatically associated with CNfs in yellow, under the physiological pH condition
(Figure S3). It is noteworthy that AuDD40 @CNf resulted in excessive conjugation of AuDD to the CNf
backbone, which led to particle aggregation. The optimal feeding ratio with the 5-fold AuDD reactant
freed AuDD24 @CNf to accommodate the non-aggregate nanoparticle; this allowed further decoration
of BSA and Ce6 to synthesize AuDD/BSA@CNf-Ce6 (Figure S4). We then prepared three types of
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CNf-grafted Ce6 (BSA@CNf-Ce6, AuDD@CNf-Ce6, and AuDD/BSA@CNf-Ce6) and calculated the
weight fractions of AuDD, Ce6, and BSA in each of the CNf construct (Table 1).
Table 1. Weight fractions of each component in the CNf-Ce6-based nanofibers.
Weight Fraction (%)

Sample
BSA@CNf-Ce6
AuDD@CNf-Ce6
AuDD/BSA@CNf-Ce6

AuDD

Ce6

BSA

24.9
25.5

5.1
4.9
5.2

4.1
3.9

The coupled weight portions of AuDD, Ce6, and BSA to CNfs were 24.9–25.5%, 4.9–5.2%,
and 3.9–4.1%, respectively. The morphology of each nanostructure was visualized using transmission
electron microscopy (TEM), which showed CNfs having widths of 10–30 nm and lengths of 100–550 nm
(Figure 2a); the AuDD attached to CNf was observed in AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6.
UV/Vis identification was conducted to confirm the binding of AuDD and Ce6 (Figure 2b). The individual
peaks in AuNP (500–600 nm) [35,40] representing AuDD, AuDD@CNf-Ce6, and AuDD/BSA@CNf-Ce6
were detected in the spectra. In addition, those of Ce6 (approximately 400 and 670 nm) [41] were
measured
Pharmaceuticsfrom
2019, free
11, x Ce6, BSA@CNf-Ce6, AuDD@CNf-Ce6, and AuDD/BSA@CNf-Ce6.
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UV/Vis spectrum
spectrum of
of all
all samples.
samples.
Figure 2. (a) TEM images of each nanostructure. (b) UV/Vis

3.2.
3.2. Investigating
Investigating the
the pH-Dependent
pH-Dependent AuDD/BSA@CNf-Ce6
AuDD/BSA@CNf-Ce6 Operation
Operation
With
pH,
With increasing
increasing evidence
evidence that
that the
the tumor
tumor microenvironment
microenvironment has
has an
an acidic
acidic extracellular
extracellular pH,
termed
pH
,
we
introduced
the
DMMA-based
self-assembly
of
AuDD/BSA@CNf-Ce6
that
safely
stores
termed pHe e, we introduced the DMMA-based self-assembly of AuDD/BSA@CNf-Ce6 that safely
stores light-activatable materials at physiological pH and discharged them at pHe to inactivate the
tumor cells. The characteristic pHe was expected to activate the dynamic disassembly of antitumor
photopoisons, photothermal AuNP, and photodynamic CNf-Ce6 (Figure 3a, upper panels). To
verify the division of AuDD/BSA@CNf-Ce6 in a pHe-dependent manner, we treated the compounds
with a pH of 7.4 and 6.8, and detected AuDD in red and CNf-Ce6 in yellow using hyperspectral
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light-activatable materials at physiological pH and discharged them at pHe to inactivate the tumor cells.
The characteristic pHe was expected to activate the dynamic disassembly of antitumor photopoisons,
photothermal AuNP, and photodynamic CNf-Ce6 (Figure 3a, upper panels). To verify the division of
AuDD/BSA@CNf-Ce6 in a pHe -dependent manner, we treated the compounds with a pH of 7.4 and 6.8,
and detected AuDD in red and CNf-Ce6 in yellow using hyperspectral imaging (Figure 3a, lower panels).
Whereas the red AuDD particles were fused with yellow CNf-Ce6 bodies because of their electrostatic
interaction under the physiological environment of pH 7.4, the AuDD particles were discharged from
the CNf-Ce6 backbones under a tumor environment of pH 6.8. The exposure to pHe resulted in a
decoupling of DMMA from AuDD, followed by positively charged dopamine-AuNP formation and
its removal from the cationic CNf-Ce6 backbone via electrostatic repulsion [42]. The zeta potential
test showed that the surface charges of CNf-Ce6-based materials changed from negative at pH 7.4 to
positive at pH 6.8 (Figure 3b), due to the decoupling of DMMA from AuDD at pH 6.8. The three types of
CNf-Ce6-based materials, BSA@CNf-Ce6, AuDD@CNf-Ce6, and AuDD/BSA@CNf-Ce6, had negative
charges of −3.9, −8.3, and −11.0 mV, respectively, under physiological conditions. All materials
displayed positive surface charges around 15.8–17.2 mV at pHe , suggesting that the tumor-associated
pH (i.e., pH 6.8) can promote electrostatic change in the CNf-Ce6-based nanostructures.
Since AuDD/BSA@CNf-Ce6 contains both photodynamic Ce6 and the photothermal AuNP,
we verified the presence of two photoactive chemicals. Figure 3c shows the pH-dependent
fluorescent responses of different Ce6-based nanostructures from 640 to 670 nm [43]. Free Ce6
had low fluorescence intensity at both pH 7.4 and 6.8 owing to its hydrophobic interaction-caused
auto-quenching [5]. BSA@CNf-Ce6 generated the highest emission peak at pH 7.4 as the fluorescence
of Ce6 was de-quenched by BSA. Importantly, while AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6
displayed comparable fluorescence intensity to the free Ce6 at pH 7.4, a noticeable increase
in their fluorescence emission was observed at pH 6.8. This was a result of the plasmonic
effect of AuDD suppressing the fluorescence of AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6 under
neutral pH conditions [41]. pHe , however, activated the dynamic cleavage (by charge–charge
repulsion, Figure 3a) and the removal of AuDD from the CNf main body. This means
that the removal of AuDD from the CNf main body allows the de-quenched state of Ce6,
resulting in an elevated Ce6-generated fluorescence. In addition, near infrared (NIR) images and
9,10-dimethylanthracene fluorescence changes (indicating singlet oxygen generation) [35] for the free
Ce6, BSA@CNf-Ce6, AuDD@CNf-Ce6, and AuDD/BSA@CNf-Ce6 demonstrated that AuDD@CNf-Ce6
and AuDD/BSA@CNf-Ce6 pH-dependently released photodynamic Ce6 (Figure 3d). At pH 7.4,
AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6 were represented by a similar color and low singlet oxygen
production when compared to self-quenched free Ce6 under radiation, a result possibly due to the
AuDD-induced plasmonic effect on Ce6 [41]. However, a color change to yellow and the singlet oxygen
production were dramatically increased at pH 6.8, suggesting that pHe enables AuDD@CNf-Ce6 and
AuDD/BSA@CNf-Ce6 to remove AuDD, followed by de-quenching and activation of Ce6. Emerging
studies have suggested that the AuNP elicits thermogenesis owing to its strong absorption in the 808 nm
region of NIR [28,36,37,44–49]. Furthermore, when the AuNP was released from AuDD/BSA@CNf-Ce6
at pH 6.8, we also examined how it has different photothermal effects in response to light (Figure 4).
As shown in Figure 4a, the samples with AuDD rose to a temperature around 50 ◦ C at pH 7.4 and 6.8.
In a time-dependent manner, the temperatures of AuDD, AuDD@CNf-Ce6, and AuDD/BSA@CNf-Ce6
increased; however, changes in BSA@CNf-Ce6 were negligible because of the absence of AuDD.
The time-dependent temperature increase in AuDD/BSA@CNf-Ce6 by NIR lasers was also visually
validated at pH 7.4 and 6.8 (Figure 4b). Together, the results suggest that AuDD/BSA@CNf-Ce6
includes both photosensitizing Ce6 (Figure 3d) and the thermogenic AuNP, and they are activated at
tumor-specific pHe under light exposure, although the photothermal difference between pH 7.4 and
6.8 is not significantly different.

Pharmaceutics 2019, 11, 258
Pharmaceutics 2019, 11, x

10 of 21
11 of 23

Figure
3. (a)
Schematicillustration
illustration and
images
of anchored/detached
AuDD from
thefrom
Figure
3. (a)
Schematic
andhyperspectral
hyperspectral
images
of anchored/detached
AuDD
CNf backbone at pH 7.4 and 6.8. (b) Changes in zeta potential of CNf-Ce6-based samples at pH 7.4
the CNf backbone at pH 7.4 and 6.8. (b) Changes in zeta potential of CNf-Ce6-based samples at
and 6.8 (mean ± SD, n = 3, ** p < 0.01 compared to pH 7.4). (c) Ce6 emission spectra (λex = 400 nm, λem =
pH 7.4 and 6.8 (mean ± SD, n = 3, ** p < 0.01 compared to pH 7.4). (c) Ce6 emission spectra
600–750 nm) for the free Ce6 or CNf-Ce6-based samples at pH 7.4 and 6.8. (d)
(λex = 400 nm, λem = 600–750 nm) for the free Ce6 or CNf-Ce6-based samples at pH 7.4 and 6.8.
9,10-Dimethylanthracene fluorescence change (Ff–Fs) in free Ce6 or CNf-Ce6-based samples at pH 7.4
(d) 9,10-Dimethylanthracene
fluorescence
change (F(λ
s ) in free Ce6 or CNf-Ce6-based samples at pH
f –F
and 6.8 (lower graphs), and
NIR Ce6 fluorescence
ex = 635 nm, λem = 720 nm) images of free Ce6 or
7.4 and 6.8 (lower graphs), and NIR Ce6 fluorescence (λex = 635 nm, λem = 720 nm) images of free Ce6
or CNf-Ce6-based samples at pH 7.4 and 6.8 (upper images). All samples were irradiated for 10 min at
a light intensity of 5.2 mW/cm2 using a 670 nm laser source.
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shows that the acidic pH of 6.8 significantly increased the quantitative cellular uptake of the

AuDD-based nanostructures, suggesting that pH is essential in endocytosis. Notably,

AuDD/BSA@CNf-Ce6 improved endocytic activity at pH 7.4 and 6.8, when compared to
non-filamentous AuDD [26,27]. In the flow cytometry analysis, Ce6-based fluorescence was
observed, and the signal from AuDD/BSA@CNf-Ce6-treated cells at pH 6.8 was approximately
6.5-fold higher than at pH 7.4 (Figure 5b). In a qualitative manner, the signal of AuNP in
AuDD/BSA@CNf-Ce6
Pharmaceutics
2019, 11, 258 was monitored at pH 7.4 and 6.8 using hyperspectral imaging analysis
12 of 21
(Figure 5c).

Figure 5. (a) Uptake value [number (N) of internalized AuDD particles per MDA-MB-231 cell for 8 h
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also showed strong red signals at pH 6.8, possibly because of its chitosan-based

positive charge in acidic conditions and its filamentous shape [47].
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against
tumor cells, MDA-MB-231 cells were treated with the nanostructure at pH 6.8 and 7.4, followed by
tumor cells, MDA-MB-231 cells were treated with the nanostructure at pH 6.8 and 7.4, followed by
irradiation with 670 nm visible light for singlet oxygen generation (PDT) and/or an 808 nm NIR laser
irradiation with 670 nm visible light for singlet oxygen generation (PDT) and/or an 808 nm NIR laser
for heat production (PTT) (Figure 7). The tumor cell death by combined phototherapy at pH 7.4
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(Figure
7a). However, AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6 dramatically reduced the tumor cell 7a).
However, AuDD@CNf-Ce6 and AuDD/BSA@CNf-Ce6 dramatically reduced the tumor cell viability
by dual light irradiation at pH 6.8 (Figure 7b), suggesting that they exhibit a synergistic effect for
tumor cell inactivation at pHe in vitro. This is because pHe leads to the active division of AuDD
and CNf-Ce6, and the wavelengths of 670 and 808 nm activate photodynamic Ce6 and photothermic
AuNP from CNf-Ce6 and AuDD, respectively. Interestingly, combined phototherapy resulted in
higher antitumor efficacy than the repeated single therapy of PDT or PTT at pH 6.8 in MDA-MB-231
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viability by dual light irradiation at pH 6.8 (Figure 7b), suggesting that they exhibit a synergistic
effect for tumor cell inactivation at pHe in vitro. This is because pHe leads to the active division of
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resulted in higher antitumor efficacy than the repeated single therapy of PDT or PTT at pH 6.8 in
MDA-MB-231 cells and human glioblastoma T98G cells (Figure S5). Moreover, the therapeutic order
cells and human glioblastoma T98G cells (Figure S5). Moreover, the therapeutic order did not affect
did not affect the phototoxicity in both tumor cell lines, a differing result from the previous
the phototoxicity in both tumor cell lines, a differing result from the previous order-dependent
order-dependent phototherapy reports [36,41]. The pHe-triggered AuDD detachment from
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AuDD/BSA@CNf-Ce6 is responsible for the dequenching event of Ce6, which allows the
responsible
for the dequenching
event of Ce6,
which allows
the order-independent
dual-phototherapy.
order-independent
dual-phototherapy.
To determine
nanostructure-induced
cytotoxicity,
the cell
To integrity
determine
nanostructure-induced
cytotoxicity,
the
cell
integrity
was
measured
for
range of
was measured for a wide range of material concentrations (Figure 7c).a wide
The results
material
concentrations
(Figure
results consistently
presented
high cellindicating
viability, regardless
consistently
presented
high 7c).
cellThe
viability,
regardless of
concentration,
that the of
concentration,
indicating
that
the
nanostructures
are
non-cytotoxic.
nanostructures are non-cytotoxic.

Figure 7. Cell viability of the MDA-MB-231 cells incubated with free Ce6 (10 μg/mL), AuDD (50
Figure 7. Cell viability of the MDA-MB-231 cells incubated with free Ce6 (10 µg/mL), AuDD (50 µg/mL),
μg/mL), and CNf-Ce6-based samples (200 μg/mL, equivalent to Ce6 10 μg/mL) at (a) pH 7.4 and (b)
and CNf-Ce6-based samples (200 µg/mL, equivalent to Ce6 10 µg/mL) at (a) pH 7.4 and (b) pH 6.8
(mean ± SD, n = 8, ** p < 0.01 compared to no laser). The cells were irradiated for 10 min at a light intensity
of 5.2 mW/cm2 using a 670 nm laser source and/or for 5 min at a light intensity of 2 W/cm2 using an 808
nm laser source. (c) Cell viability of the MDA-MB-231 cells incubated with AuDD or CNf-Ce6-based
samples for 24 h at 37 ◦ C without light irradiation (mean ± SD, n = 8, ** p < 0.01 compared to AuDD).
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pH 6.8 (mean ± SD, n = 8, ** p < 0.01 compared to no laser). The cells were irradiated for 10 min at a
light intensity of 5.2 mW/cm2 using a 670 nm laser source and/or for 5 min at a light intensity of 2
2 using an 808 nm laser source. (c) Cell viability of the MDA-MB-231 cells incubated with
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AuDD or CNf-Ce6-based samples for 24 h at 37 °C without light irradiation (mean ± SD, n = 8, ** p <
0.01 compared to AuDD).
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Figure 8. Flow cytometry results of apoptosis/necrosis using control (untreated) or
Figure 8. Flow cytometry results of apoptosis/necrosis using control (untreated) or AuDD/BSA@CNf-Ce6
AuDD/BSA@CNf-Ce6 (200 μg/mL, equivalent to Ce6 10 μg/mL) under PDT
(670 nm, 5.2 mW/cm2)
(200 µg/mL, equivalent to Ce6 10 µg/mL)
under PDT (670 nm, 5.2 mW/cm2 ) treatment, PTT (808 nm,
2
treatment, PTT (808 nm, 2 W/cm ) treatment, or combined PDT/PTT treatment. The results of
2 W/cm2 ) treatment, or combined PDT/PTT treatment. The results of apoptosis/necrosis were determined
apoptosis/necrosis were determined using Annexin V-FITC and PI staining. Each quadrant is
using Annexin V-FITC and PI staining. Each quadrant is indicated as follows: lower left, live cells; lower
right, early apoptotic cells; upper left, dead cells; upper right, late apoptotic/necrotic cells.

3.5. In Vivo Antitumor Study
Encouraged by the results of the in vitro tumor inhibition activity by AuDD/BSA@CNf-Ce6,
animal experiments were performed. First, to assess tumor-targeting efficiency, the free Ce6, BSA@CNf-Ce6,
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BSA@CNf-Ce6, and AuDD/BSA@CNf-Ce6 were administered to MDA-MB-231 tumor-bearing nude
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(b) Fluorescence images of free Ce6, BSA@CNf-Ce6, or AuDD/BSA@CNf-Ce6 into organs harvested from
MDA-MB-231 tumor-bearing nude mice at 8 h post-injection. (c) Total photon counts per centimeter
squared per steradian (p/s/cm2 /sr; measured using an Image Station 4000 MM) of the organs harvested
from MDA-MB-231 tumor-bearing nude mice at 8 h post-injection (mean ± SD, n = 5, ** p < 0.01
compared to free Ce6).
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dashed circles. (b) Fluorescence images of free Ce6, BSA@CNf-Ce6, or AuDD/BSA@CNf-Ce6 into
organs harvested from MDA-MB-231 tumor-bearing nude mice at 8 h post-injection. (c) Total photon
counts per centimeter squared per steradian (p/s/cm2/sr; measured using an Image Station 4000 MM)
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from MDA-MB-231 tumor-bearing nude mice at 8 h post-injection (mean 17
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SD, n = 5, ** p < 0.01 compared to free Ce6).
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in vitro cytotoxicity test results (Figure 7c). Overall, the data have reinforced the tumor-killing efficacy
and safety of dual PDT/PTT-intended AuDD/BSA@CNf-Ce6 treatment in vivo.
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groups (Figure 11c), a result that aligns with the in vitro cytotoxicity test results (Figure 7c). Overall,
the tumor-killing efficacy and safety of dual PDT/PTT-intended
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saline). (d) Optical photographs of MDA-MB-231 tumor-bearing nude mice after 7 d of injection.
Tumor sites are indicated by the dashed circles.

4. Conclusions

Herein, AuDD/BSA@CNf-Ce6 was strategically designed and developed to selectively release
phototoxins against tumors. Its backbone was composed of worm-like, biocompatible CNf, covalently
conjugated to the photodynamic Ce6. In addition, BSA and heat-generating AuNP were electrostatically
linked to the chitosan body to improve the blood circulation of the carrier. The interaction between
AuDD/BSA@CNf-Ce6 and tumor-specific pHe initiated the separation and launch of CNf-Ce6 and AuDD,
which synergistically induced tumor damage upon exposure to different wavelengths of radiation.
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Collectively, pHe -sensitive AuDD/BSA@CNf-Ce6 engineered for combined PDT and PTT might unlock
the maximum therapeutic potential against tumor, thus functioning as a promising next-generation DDS
tool. We will conduct a detailed in vivo study and a pharmacokinetic study in the future.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/6/258/s1,
Figure S1: 1 H-NMR spectrum of dopamine-DMMA (300 MHz, CDCl3). Figure S2: Particle size distribution and
TEM image of AuDD. Figure S3: Hyperspectral images of AuDD, CNf, and the different types of AuDD@CNf. The
linked amount (%) of each AuDD to CNf is 7% (AuDD7@CNf), 24% (AuDD24@CNf) and 40% (AuDD40@CNf).
Figure S4: Binding efficiency of AuDD to CNf-Ce6 with different feeding amounts. The optimal feeding ratio
of AuDD for AuDD@CNf-Ce6 is indicated by the dashed rectangle. Figure S5: Cell viability determined by
the CCK-8 assay of (a) MDA-MB-231 cells and (b) T98G cells incubated with AuDD/BSA@CNf-Ce6 (200 µg/mL,
equivalent to Ce6 10 µg/mL) at pH 6.8 (mean ± SD, n = 8, ** p < 0.01 compared to dual-PDT irradiation). The cells
were irradiated for 10 min at a light intensity of 5.2 mW/cm2 using a 670-nm laser source for PDT and/or for 5 min
at a light intensity of 2 W/cm2 using an 808-nm laser source for PTT. Table S1: Degree of deacetylation and amine
concentration of chitosan nanofiber (CNf) obtained by Fourier transform infrared spectroscopy and titration, n = 3,
mean ± standard deviation).
Author Contributions: H.S.Y. and H.P. contributed equally to this work as first authors. All authors contributed
to the conduct of the experiments, data analyses, and the preparation of the manuscript.
Funding: This work was financially supported by the National Research Foundation of Korea (NRF) grant funded by the
Korea government (MSIT) (grant number: NRF-2018R1A2B6000970 and NRF-2015R1A4A1042350). J.P. acknowledges
support from the Korea Research Institute of Chemical Technology (KRICT) core project (SI1941-20, KK1941-30).
Conflicts of Interest: The authors declare no competing financial interests.

References
1.
2.

3.

4.
5.

6.
7.
8.

9.
10.

11.

Tian, B.; Wang, C.; Zhang, S.; Feng, L.; Liu, Z. Photothermally enhanced photodynamic therapy delivered by
nano-graphene oxide. ACS Nano 2011, 5, 7000–7009. [CrossRef] [PubMed]
Liu, J.; Zheng, X.; Yan, L.; Zhou, L.; Tian, G.; Win, W.; Wang, L.; Liu, Y.; Hu, Z.; Gu, Z.; et al. Bismuth sulfide
nanorods as a precision nanomedicine for in vivo multimodal imaging-guided photothermal therapy of
tumor. ACS Nano 2015, 9, 696–707. [CrossRef] [PubMed]
Li, J.; Hu, Y.; Yang, J.; Wei, P.; Sun, W.; Shen, M.; Zhang, G.; Shi, X. Hyaluronic acid-modified Fe3 O4 @Au
core/shell nanostars for multimodal imaging and photothermal therapy of tumors. Biomaterials 2015, 38, 10–21.
[CrossRef] [PubMed]
Dou, Q.Q.; Teng, C.P.; Ye, E.; Loh, X.J. Effective near-infrared photodynamic therapy assisted by upconversion
nanoparticles conjugated with photosensitizers. Int. J. Nanomed. 2015, 10, 419–432.
Park, W.; Park, S.J.; Cho, S.; Shin, H.; Jung, Y.S.; Lee, B.; Na, K.; Kim, D.H. Intermolecular structural change
for thermoswitchable polymeric photosensitizer. J. Am. Chem. Soc. 2016, 138, 10734–10737. [CrossRef]
[PubMed]
Jun, H.; Lee, H.J.; Shin, B.S.; Park, C.W. Preparation and in vivo characterization of dual release tablet
containing sarpogrelate. J. Pharm. Investig. 2018, 48, 363–372. [CrossRef]
Hwang, H.S.; Shin, H.; Han, J.; Na, K. Combination of photodynamic therapy (PDT) and anti-tumor immunity
in cancer therapy. J. Pharm. Investig. 2018, 48, 143–151. [CrossRef]
Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.;
Schmidt, M.; et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus
letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer
(PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015, 16, 25–35. [CrossRef]
Xu, X.; Ho, W.; Zhang, X.; Bertrand, N.; Farokhzad, O. Cancer nanomedicine: From targeted delivery to
combination therapy. Trends Mol. Med. 2015, 21, 223–232. [CrossRef]
Kalluru, P.; Vankayala, R.; Chiang, C.S.; Hwang, K.C. Photosensitization of singlet oxygen and in vivo
photodynamic therapeutic effects mediated by PEGylated W18 O49 nanowires. Angew. Chem. Int. Ed.
2013, 52, 12332–12336. [CrossRef]
Han, H.S.; Choi, K.Y.; Lee, H.; Lee, M.; An, J.Y.; Shin, S.; Kwon, S.; Lee, D.S.; Park, J.H. Gold-nanoclustered
hyaluronan nano-assemblies for photothermally maneuvered photodynamic tumor ablation. ACS Nano
2016, 10, 10858–10868. [CrossRef]

Pharmaceutics 2019, 11, 258

12.
13.

14.

15.

16.

17.
18.
19.

20.
21.
22.

23.

24.

25.

26.
27.
28.
29.

30.
31.

20 of 21

Sun, W.; He, S.; Martínez-Romero, C.; Kouznetsova, J.; Tawa, G.; Xu, M.; Shinn, P.; Fisher, E.; Long, Y.; Motabar, O.
Synergistic drug combination effectively blocks ebola virus infection. Antivir. Res. 2017, 137, 165–172. [CrossRef]
Hayashi, K.; Nakamura, M.; Miki, H.; Ozaki, S.; Abe, M.; Matsumoto, T.; Kori, T.; Ishimura, K.
Photostable iodinated silica/porphyrin hybrid nanoparticles with heavy-atom effect for wide-field
photodynamic/photothermal therapy using single light source. Adv. Funct. Mater. 2014, 24, 503–513.
[CrossRef]
Jang, B.; Park, J.Y.; Tung, C.H.; Kim, I.H.; Choi, Y. Gold nanorod-photosensitizer complex for near-infrared
fluorescence imaging and photodynamic/photothermal therapy in vivo. ACS Nano 2011, 5, 1086–1094.
[CrossRef] [PubMed]
Goel, S.; Ferreira, C.A.; Chen, F.; Ellison, P.A.; Siamof, C.M.; Barnhart, T.E.; Cai, W. Activatable hybrid
nanotheranostics for tetramodal imaging and synergistic photothermal/photodynamic therapy. Adv. Mater.
2018, 30, 1704367. [CrossRef] [PubMed]
Wisser, D.; Wisser, F.M.; Raschke, S.; Klein, N.; Leistner, M.; Grothe, J.; Brunner, E.; Kaskel, S. Biological
chitin-MOF composites with hierarchical pore systems for air-filtration applications. Angew. Chem. Int. Ed.
2015, 54, 12588–12591. [CrossRef] [PubMed]
Malerba, M.; Cerana, R. Recent applications of chitin- and chitosan-based polymers in plants. Polymers
2019, 11, 839. [CrossRef]
Bozuyuk, U.; Yasa, O.; Yasa, I.C.; Ceylan, H.; Kizilel, S.; Sitti, M. Light-triggered drug release from 3D-printed
magnetic chitosan microswimmers. ACS Nano 2018, 12, 9617–9625. [CrossRef] [PubMed]
Tran, T.H.; Nguyen, H.-L.; Hwang, D.S.; Lee, J.Y.; Cha, H.G.; Koo, J.M.; Hwang, S.Y.; Park, J.; Oh, D.X. Five
different chitin nanomaterials from identical source with different advantageous functions and performances.
Carbohydr. Polym. 2019, 205, 392–400. [CrossRef] [PubMed]
Oh, D.X.; Kim, S.; Lee, D.; Hwang, D.S. Tunicate-mimetic nanofibrous hydrogel adhesive with improved wet
adhesion. Acta Biomater. 2015, 20, 104–112. [CrossRef]
Lee, E.S.; Gao, Z.; Bae, Y.H. Recent progress in tumor pH targeting nanotechnology. J. Control. Release
2008, 132, 164–170. [CrossRef] [PubMed]
Oh, N.M.; Kwag, D.S.; Oh, K.T.; Youn, Y.S.; Lee, E.S. Electrostatic charge conversion processes in engineered
tumor-identifying polypeptides for targeted chemotherapy. Biomaterials 2012, 33, 1884–1893. [CrossRef]
[PubMed]
Tang, S.; Meng, Q.; Sun, H.; Su, J.; Yin, Q.; Zhang, Z.; Yu, H.; Chen, L.; Gu, W.; Li, Y. Dual pH-sensitive
micelles with charge-switch for controlling cellular uptake and drug release to treat metastatic breast cancer.
Biomaterials 2017, 114, 44–53. [CrossRef] [PubMed]
Mackay, J.A.; Chen, M.; Mcdaniel, J.R.; Liu, W.; Simnick, A.J.; Chilkoti, A. Self-assembling chimeric
polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater.
2009, 8, 993–999. [CrossRef] [PubMed]
Moitra, P.; Kumar, K.; Kondaiah, P.; Bhattacharya, S. Efficacious anticancer drug delivery mediated by a
pH-sensitive self-assembly of a conserved tripeptide derived from tyrosine kinase NGF receptor. Angew.
Chem. Int. Ed. 2014, 53, 1113–1117. [CrossRef]
Geng, Y.; Dalhaimer, P.; Cai, S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D.E. Shape effects of filaments versus
spherical particles in flow and drug delivery. Nat. Nanotechnol. 2007, 2, 249–255. [CrossRef] [PubMed]
Zhang, P.; Cheetham, A.G.; Lin, Y.A.; Cui, H. Self-assembled tat nanofibers as effective drug carrier and
transporter. ACS Nano 2013, 7, 5965–5977. [CrossRef]
Kennedy, L.C.; Bickford, L.R.; Lewinski, N.A.; Coughlin, A.J.; Hu, Y.; Day, E.S.; West, J.L.; Drezek, R.A. A new
era for cancer treatment: Gold-nanoparticle-mediated thermal therapies. Small 2011, 7, 169–183. [CrossRef]
Yata, T.; Takahashi, Y.; Tan, M.; Nakatsuji, H.; Ohtsuki, S.; Murakami, T.; Imahori, H.; Umeki, Y.; Shiomi, T.;
Takakura, Y.; et al. DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA
hydrogel for tumor photothermal immunotherapy. Biomaterials 2017, 146, 136–145. [CrossRef]
Owens, D.E., III; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric
nanoparticles. Int. J. Pharm. 2006, 307, 93–102. [CrossRef]
Torres-Rendon, J.G.; Femmer, T.; De Laporte, L.; Tigges, T.; Rahimi, K.; Gremse, F.; Zafarnia, S.; Lederle, W.;
Ifuku, S.; Wessling, M.; et al. Bioactive gyroid scaffolds formed by sacrificial templating of nanocellulose and
nanochitin hydrogels as instructive platforms for biomimetic tissue engineering. Adv. Mater. 2015, 27, 2989–2995.
[CrossRef] [PubMed]

Pharmaceutics 2019, 11, 258

32.

33.
34.

35.
36.

37.

38.

39.

40.
41.

42.

43.
44.
45.

46.
47.

48.

49.

21 of 21

Amjadi, S.; Emaminia, S.; Heyat Davudian, S.; Pourmohammad, S.; Hamishehkar, H.; Roufegarinejad, L.
Preparation and characterization of gelatin-based nanocomposite containing chitosan nanofiber and ZnO
nanoparticles. Carbohydr. Polym. 2019, 216, 376–384. [CrossRef] [PubMed]
Lee, U.Y.; Youn, Y.S.; Park, J.; Lee, E.S. Y-Shaped ligand-driven gold nanoparticles for highly efficient tumoral
uptake and photothermal ablation. ACS Nano 2014, 8, 12858–12865. [CrossRef] [PubMed]
Balagangadharan, K.; Trivedi, R.; Vairamani, M.; Selvamurugan, N. Sinapic acid-loaded chitosan nanoparticles
in polycaprolactone electrospun fibers for bone regeneration in vitro and in vivo. Carbohydr. Polym.
2019, 216, 1–16. [CrossRef] [PubMed]
Park, S.Y.; Baik, H.J.; Oh, Y.T.; Oh, K.T.; Youn, Y.S.; Lee, E.S. A smart polysaccharide/drug conjugate for
photodynamic therapy. Angew. Chem. Int. Ed. 2011, 50, 1644–1647. [CrossRef] [PubMed]
Zhang, D.; Wu, M.; Zeng, Y.; Wu, L.; Wang, Q.; Han, X.; Liu, X.; Liu, J. Chlorin e6 conjugated poly(dopamine)
nanospheres as PDT/PTT dual-modal therapeutic agents for enhanced cancer therapy. ACS Appl. Mater.
Interfaces 2015, 7, 8176–8187. [CrossRef] [PubMed]
Yuan, Y.; Wang, Z.; Cai, P.; Liu, J.; Liao, L.D.; Hong, M.; Chen, X.; Thakor, N.; Liu, B. Conjugated polymer and
drug co-encapsulated nanoparticles for chemo- and photo-thermal combination therapy with two-photon
regulated fast drug release. Nanoscale 2015, 7, 3067–3076. [CrossRef] [PubMed]
Wu, J.; Zheng, K.; Huang, X.; Liu, J.; Liu, H.; Boccaccini, A.R.; Wan, Y.; Guo, X.; Shao, Z. Thermally triggered
injectable chitosan/silk fibroin/bioactive glass nanoparticle hydrogels for in-situ bone formation in rat
calvarial bone defects. Acta Biomater. 2019, 91, 60–71. [CrossRef]
Kang, T.; Oh, D.X.; Heo, J.; Lee, H.K.; Choy, S.; Hawker, C.J.; Hwang, D.S. Formation, removal, and
reformation of surface coatings on various metal oxide surfaces inspired by mussel adhesives. ACS Appl.
Mater. Interfaces 2015, 7, 24656–24662. [CrossRef]
MacLeod, M.J.; Goodman, A.J.; Ye, H.Z.; Nguyen, H.V.; Voorhis, T.V.; Johnson, J.A. Robust gold nanorods
stabilized by bidentate N-heterocyclic-carbene-thiolate ligands. Nat. Chem. 2018, 11, 57–63. [CrossRef]
Wang, S.; Huang, P.; Nie, L.; Xing, R.; Liu, D.; Wang, Z.; Lin, J.; Chen, S.; Niu, G.; Lu, G.; et al. Single continuous
wave laser induced photodynamic/plasmonic photothermal therapy using photosensitizer-functionalized
gold nanostars. Adv. Mater. 2013, 25, 3055–3061. [CrossRef] [PubMed]
Ku, E.B.; Lee, D.J.; Na, K.; Choi, S.W.; Youn, Y.S.; Bae, S.K.; Oh, K.T.; Lee, E.S. pH-Responsive globular
poly(ethylene glycol) for photodynamic tumor therapy. Colloids Surf. B 2016, 148, 173–180. [CrossRef]
[PubMed]
Park, H.; Na, K. Conjugation of the photosensitizer chlorin e6 to pluronic F127 for enhanced cellular
internalization for photodynamic therapy. Biomaterials 2013, 34, 6992–7000. [CrossRef] [PubMed]
O’Neal, D.P.; Hirsch, L.R.; Halas, N.J.; Payne, J.D.; West, J.L. Photo-thermal tumor ablation in mice using
near infrared-absorbing nanoparticles. Cancer Lett. 2004, 209, 171–176. [CrossRef] [PubMed]
Lee, C.; Hwang, H.S.; Lee, S.; Kim, B.; Kim, J.O.; Oh, K.T.; Lee, E.S.; Choi, H.G.; Youn, Y.S. Rabies virus-inspired
silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv. Mater.
2017, 29, 1605563. [CrossRef]
Verma, A.; Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 66, 12–21.
[CrossRef]
Razavi, S.; Seyedebrahimi, R.; Jahromi, M. Biodelivery of nerve growth factor and gold nanoparticles
encapsulated in chitosan nanoparticles for schwann-like cells differentiation of human adipose-derived stem
cells. Biochem. Biophys. Res. Commun. 2019, 513, 681–687. [CrossRef]
Ifuku, S.; Tsukiyama, Y.; Yukawa, T.; Egusa, M.; Kaminaka, H.; Izawa, H.; Morimoto, M.; Saimoto, H. Facile
preparation of silver nanoparticles immobilized on chitin nanofiber surfaces to endow antifungal activities.
Carbohydr. Polym. 2015, 117, 813–817. [CrossRef]
Mousser, H.B.; Hamoudi, A.; Fleutot, S.; Fontana, S.; Cleymand, F.; Mousser, A. The effect of thermal
treatment on the acid neutralizing capacity of newberyite: Structural assessment and kinetics of the HCl
neutralization reaction. J. Pharm. Investig. 2018, 48, 575–584. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

